WELCOME TO The PHARMACEUTICAL REPORT
Pharmaceutical Compliance Monitor
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Red River Biorefinery | October 06, 2020
The Red River Biorefinery (RRB) announced today that it has expanded production to supply ethanol that meets the U.S. Pharmacopeia (USP) purity and quality standards to the hand sanitizer market. To help meet the increase in global demand for hand sanitizer products due to COVID-19, RRB is now supplying hand sanitizer manufacturers with safe, high-quality ethanol products with one of the lowest carbon footprints available on the market today. It is extremely gratifying to have a local producer s...
Antares Pharma, Inc. | February 04, 2022
Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act.
TLANDO® was granted tentative approval from the FDA as a twice-daily...
Upadhye Cwik LLP | July 02, 2020
The COVID-19 pandemic continues to turn the world upside down. And when upside down, the legal issues surrounding pharmaceuticals and the FDA become apparent. We identify a few areas that our law firm is working on for clients.
Our patent work remains busy helping clients with rationalizing patent portfolios, conducting infringement-mapping exercises to find potential licensing revenues, and patent litigation to enforce patent rights. Interestingly we see some clients not cutting ...
AlzeCure Pharma | September 28, 2020
CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE